Cala Health’s kIQ Plus now offers three stimulation modes and a calibration before each use, and it’s available across the US ...

German biotech MODAG won for pairing a CE-marked diagnostic with a drug candidate that targets the same protein.

Adjusting for how advanced patients’ disease was at the start lifts the Phase 2 result. The method was added after the trial ...

A day is a long time to study a donated human brain. Bexorg thinks it’s still too short. On 7 October, the Connecticut-based ...

Shmouni and Koehl Robinson unpack peptide medicine, from GLP-1s and BPC-157 to evidence, safety, regulation and personalized ...

BodySpec’s new storefront targets muscle loss from GLP-1 weight loss drugs, with scans said to take about 12 minutes.

A Censuswide survey commissioned by PortionIQ finds confidence is lower among longer-term users, though it’s a snapshot from one brand.

VectorY is growing PIONEER-ALS from 12 to 36 participants to test VTx-002, an antibody therapy aimed at the protein TDP-43.

Forget the diagnosis count. The researcher who helped the WHO reframe aging says function, not disease, is the better yardstick.

QIMA Life Sciences launches SQINGEVITY, bringing biological testing and clinical studies together to examine claims about ...

The Austin-based microbiome testing company raised a $33M Series B, and adults now outnumber babies in its testing volume.

A five-year NIA grant puts UCLA Health in charge of checking whether AI tools for Alzheimer’s care work before they spread.